Talaromyces marneffei infection in an HIV infected patient with hematological malignancy - first report from Turkey

New Microbiol. 2023 Sep;46(3):311-314.

Abstract

T.marneffei, encountered mostly in Southeast Asia, leads to a systemic infection, especially in immunocompromised individuals such as HIV-infected patients with low CD4 level. A 32-year-old male patient, residing in Hong Kong for the last two years, admitted with fever, cough, weakness, and weight loss. Physical examination revealed bilateral cervical and axillary multiple lymph nodes and hepatosplenomegaly. Screening of the pancytopenic patient revealed HIV infection. Histopathological examination of the cervical lymph node revealed plasmoblastic lymphoma. Blood and urine cultures remained sterile. Antiretroviral therapy was started. Fungal hyphae were detected in Gram staining of hemocultures taken in the third week due to ongoing fever, and antifungal therapy was started empirically. Red pigment around colonies on Sabouraud dextrose agar and microscopic appearance arose suspicion of Talaromyces spp. T.marneffei was identified by ITS 1-4 sequence analysis. Chemotherapy was started when fungemia was controlled. On the fifth day of chemotherapy, the patient's general condition deteriorated, broad-spectrum antibiotics were started and the patient was transferred to ICU. The cultures remained sterile and he expired five days later. In conclusion, although talaromycosis is not endemic in Turkey, it should be considered in patients with travel history to endemic regions and/or an underlying immunosuppressive disease such as HIV infection.

Keywords: HIV; Talaromyces marneffei; hematological malignancy.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-Bacterial Agents
  • HIV Infections* / complications
  • HIV Infections* / drug therapy
  • Humans
  • Male
  • Mycoses* / diagnosis
  • Mycoses* / drug therapy
  • Turkey

Substances

  • Anti-Bacterial Agents

Supplementary concepts

  • talaromycosis